Form 4: Recursion CEO Najat Khan Sells Shares via 10b5-1 Plan

Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock under a pre-arranged trading plan.

Summary

• CEO and President Najat Khan sold 23,588 shares of Recursion Pharmaceuticals (RXRX) Class A Common Stock.
• The shares were sold at a weighted average price of $3.5806 per share.
• The transaction was executed on June 5, 2026, pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Following the sale, the reporting person retains beneficial ownership of 2,175,796 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is a routine administrative action for corporate officers.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the CEO's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice and generally do not reflect a change in strategic outlook, but rather personal financial planning.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to divest shares while maintaining regulatory compliance and transparency.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small fraction of the CEO's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Najat Khan, Biotech